Milestone's Cardamyst Launch Gains Traction, Funding Boosts Runway
Event summary
- Milestone Pharmaceuticals received FDA approval for CARDAMYST (etripamil) nasal spray in December 2025, marking the first new treatment option for PSVT in 30 years.
- The company reported $1.5 million in revenue for the fourth quarter and full year 2025, primarily from a milestone payment related to the FDA approval.
- Milestone secured $75 million from RTW Royalty I DAC and $19 million from ATM sales and warrant exercises, providing a pro forma cash runway into late 2027.
- The company deployed its national sales force within eight weeks of approval and reports positive initial engagement from healthcare providers and payers.
The big picture
Milestone's CARDAMYST represents a rare opportunity in a relatively stagnant cardiovascular treatment space, addressing a significant unmet need for a rapid-acting, self-administered PSVT therapy. The company's ability to execute on its commercial launch plan and secure favorable reimbursement will be crucial for long-term success. The recent financing provides a buffer, but the company's burn rate and ability to generate sustainable revenue will be key factors for investors to monitor.
What we're watching
- Market Adoption
- The pace at which CARDAMYST gains market share will be critical, as initial prescription data will be a key indicator of physician and patient acceptance, and payer coverage decisions will significantly impact revenue generation.
- Regulatory Risk
- The EMA’s decision on etripamil’s marketing authorization application, expected in the first half of 2027, will determine the product’s commercial potential in Europe and could impact investor sentiment.
- AFib Expansion
- Milestone’s progress in the Phase 3 program for AFib-RVR will be closely watched, as success in this indication could significantly expand the product’s addressable market and long-term revenue potential.
Related topics